CN110381953A - 硫化寡糖在制备治疗手术后肝细胞癌病患的药物的用途 - Google Patents

硫化寡糖在制备治疗手术后肝细胞癌病患的药物的用途 Download PDF

Info

Publication number
CN110381953A
CN110381953A CN201880014397.6A CN201880014397A CN110381953A CN 110381953 A CN110381953 A CN 110381953A CN 201880014397 A CN201880014397 A CN 201880014397A CN 110381953 A CN110381953 A CN 110381953A
Authority
CN
China
Prior art keywords
hepatocellular carcinoma
purposes
drug
patients
blood vessels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880014397.6A
Other languages
English (en)
Chinese (zh)
Inventor
张世忠
赖冠郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medigen Biotechnology Corp
Original Assignee
Medigen Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigen Biotechnology Corp filed Critical Medigen Biotechnology Corp
Publication of CN110381953A publication Critical patent/CN110381953A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201880014397.6A 2017-03-01 2018-02-24 硫化寡糖在制备治疗手术后肝细胞癌病患的药物的用途 Pending CN110381953A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762465170P 2017-03-01 2017-03-01
US62/465,170 2017-03-01
US201762504552P 2017-05-11 2017-05-11
US62/504,552 2017-05-11
US201762551770P 2017-08-29 2017-08-29
US62/551,770 2017-08-29
PCT/CN2018/077105 WO2018157762A1 (en) 2017-03-01 2018-02-24 Use of sulfated oligosaccharides in the manufacture of a medicament for treating patients with hepatocellular carcinoma after surgical resection

Publications (1)

Publication Number Publication Date
CN110381953A true CN110381953A (zh) 2019-10-25

Family

ID=63357147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880014397.6A Pending CN110381953A (zh) 2017-03-01 2018-02-24 硫化寡糖在制备治疗手术后肝细胞癌病患的药物的用途

Country Status (6)

Country Link
US (1) US10842804B2 (https=)
JP (1) JP6948080B2 (https=)
KR (1) KR102265159B1 (https=)
CN (1) CN110381953A (https=)
TW (1) TWI693071B (https=)
WO (1) WO2018157762A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113160911A (zh) * 2021-02-26 2021-07-23 杭州臻合健康科技有限公司 一种用于术前肝功能耐受性分析的评估系统
CN117476246B (zh) * 2023-12-25 2024-04-19 福建大数据一级开发有限公司 基于多类型复发事件的患者生存分析方法、介质及装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167434A1 (zh) * 2011-06-09 2012-12-13 基亚生物科技股份有限公司 用于抑制肝癌复发、恶化或转移之医药组成物
CN103788141A (zh) * 2004-03-04 2014-05-14 普罗吉恩制药有限公司 硫酸化寡聚糖衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103788141A (zh) * 2004-03-04 2014-05-14 普罗吉恩制药有限公司 硫酸化寡聚糖衍生物
WO2012167434A1 (zh) * 2011-06-09 2012-12-13 基亚生物科技股份有限公司 用于抑制肝癌复发、恶化或转移之医药组成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIU C.J.等: "Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after resection:A randomized phase II trial for safety and optimal dosage", 《JOURNAL OF HEPATOLOGY》 *
廖竞宇等: "免疫卡控点与HCC抗肿瘤治疗", 《免疫学杂志》 *
肖楚瑶等: "新型抗肿瘤药:PI-88 及其类似物", 《国际药学研究杂志》 *

Also Published As

Publication number Publication date
JP6948080B2 (ja) 2021-10-13
TW201840324A (zh) 2018-11-16
WO2018157762A1 (en) 2018-09-07
KR102265159B1 (ko) 2021-06-17
KR20190120339A (ko) 2019-10-23
JP2020509035A (ja) 2020-03-26
US10842804B2 (en) 2020-11-24
TWI693071B (zh) 2020-05-11
US20180250317A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
US20250154274A1 (en) Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
Cohen et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
US20260092114A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20240026003A1 (en) Methods for treating cancer with anti-pd-1 antibodies
US20210047409A1 (en) Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies
JP2020514311A (ja) がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ
JP2013067645A (ja) 転移性乳癌の治療
US20180134803A1 (en) Treatment of her2-positive breast cancer
US20260098087A1 (en) Dosages of emactuzumab
Zhang et al. A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028
CN110381953A (zh) 硫化寡糖在制备治疗手术后肝细胞癌病患的药物的用途
JP2021531330A (ja) 組合せ療法を使用してがんを治療する方法
Mateeva et al. Management of primary cutaneous lymphomas during the COVID-19 pandemic
RU2846266C2 (ru) Способы лечения злокачественного новообразования с использованием антител против pd-1
KR20240162547A (ko) 화학요법과 조합하여 항-pd-l1 항체를 사용하여 담도암을 치료하는 방법
Dai et al. Capecitabine and Oxaliplatin (CAPEOX) combined with Sintilimab plus bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or esophagogastric junction adenocarcinoma: study protocol of a single-arm, phase Ib/II trial
Sundahl et al. Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
Redmond Protocol Number: PHS IRB: 15-166
EA041548B1 (ru) Способ лечения локальных поздних стадий солидных опухолей или метастатических солидных опухолей
Non-IND Clinical Protocol CA001030
KN026 et al. A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of KN026 in Combination with Chemotherapy in Subjects with HER2-positive Gastric Cancer (including Adenocarcinoma of Esophagogastric Junction) Who Have Failed First-line Treatment
HK40018435A (en) Treatment of her2-positive breast cancer
CN101405029A (zh) 转移性乳腺癌的治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20191025